Treatment characteristics
| Treatment . | λ (n = 404) . | κ (n = 153) . | P . |
|---|---|---|---|
| Conditioning regimen, n (%) | .52 | ||
| Melphalan 200 mg/m2 | 289 (72) | 101 (66) | |
| Melphalan <200 mg/m2 | 115 (28) | 55 (30) | |
| Other | 0 | 6 (4) | |
| Timing of transplant from diagnosis, n (%) | .0061 | ||
| <6 mo | 303 (75) | 91 (62) | .0032 |
| 6-12 mo | 62 (15) | 41 (27) | |
| >12 mo | 39 (10) | 17 (11) | |
| Pretransplantation chemotherapy, n (%) | .0018 | ||
| Untreated | 249 (62) | 71 (46) | .0015 |
| Corticosteroid only | 38 (10) | 18 (12) | |
| Melphalan based | 25 (6) | 5 (3) | |
| IMiD based | 26 (6) | 10 (6) | |
| Bortezomib based | 58 (14) | 44 (29) | |
| Other | 9 (2) | 5 (3) |
| Treatment . | λ (n = 404) . | κ (n = 153) . | P . |
|---|---|---|---|
| Conditioning regimen, n (%) | .52 | ||
| Melphalan 200 mg/m2 | 289 (72) | 101 (66) | |
| Melphalan <200 mg/m2 | 115 (28) | 55 (30) | |
| Other | 0 | 6 (4) | |
| Timing of transplant from diagnosis, n (%) | .0061 | ||
| <6 mo | 303 (75) | 91 (62) | .0032 |
| 6-12 mo | 62 (15) | 41 (27) | |
| >12 mo | 39 (10) | 17 (11) | |
| Pretransplantation chemotherapy, n (%) | .0018 | ||
| Untreated | 249 (62) | 71 (46) | .0015 |
| Corticosteroid only | 38 (10) | 18 (12) | |
| Melphalan based | 25 (6) | 5 (3) | |
| IMiD based | 26 (6) | 10 (6) | |
| Bortezomib based | 58 (14) | 44 (29) | |
| Other | 9 (2) | 5 (3) |
IMiD, immunomodulatory drug.